Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients

Biological Psychiatry

Volumn 42, Issue 1, 1997, Pages 6-12

  Lindenmayer, Jean Pierre ^a,d   Adityanjee, ^b   Vital Herne, Marc ^a   Bark, Nigel ^c   Grochowski, Sandra ^c   Moynihan, Nancy ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

Clozapine; Cortisol response; Metachlorophenylpiperazine; Schizophrenia; Serotonin; Treatment refractory

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CHLORAL HYDRATE; CLOZAPINE; HYDROCORTISONE; NEUROLEPTIC AGENT; PLACEBO; PROLACTIN; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC HETEROGENEITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN; SEROTONIN AGONISTS;

EID: 0030841774     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00296-X     Document Type: Article

References (42)

1. Alpert M, Rush M (1983): Comparison of affect in Parkinson's disease and schizophrenia. Psychopharmacol Bull 18:118-120.
2. Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, Price LH (1994): Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (MCPP) in depressed patients and healthy control subjects. Am J Psychiatry 151:1626-1630.
3. Banki CM, Arato M, Papp Z, Kurcz M (1984): Cerebrospinal fluid amine metabolites and neuroendocrine changes in psychosis and suicide. In Usdin E, Carlsson A, Dahlstrom A, (eds), Catecholamines: Neuropharmacology and Central Nervous System - Therapeutic Aspects New York: Alan Liss, pp 153-159.
4. Bleich A, Brown S, Kahn RS, van Praag HM (1988): The role of serotonin in schizophrenia. Schizophr Bull 14:297-315.
5. Bleich A, Brown S-L, van Praag HM (1992): A Serotonergic Theory of Schizophrenia. In van Praag HM, Brown S-L (eds), The Role of Serotonin in Psychiatric Disorders. New York: Brunner Mazel, pp 183-214.
6. Breier A, Kirkpatrick B, Buchanan RW (1993): Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry 34:492-494.
7. Bryk A, Raudenbush S (1992): Hierarchical Linear Models: Applications and Data Analysis Methods. Newbury Park, NJ: Sage Publications.
8. Canton H, Verriele L, Colpaert FC (1990): Binding of typical and atypical antipsychotics to 5-HT1c and 5-HT2 sites. Clozapine potently interacts with 5-HT1c sites. Eur J Pharmacol 191:93-96.
9. Ceulmans D, Gelders Y, Hoppenbrouwers M-L, Reyntjens A, Jansen P (1985): Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology 85:329-332.
10. Charney S, Wood S, Goodman W, Heninger G (1987): Serotonin function in anxiety. II. Effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14-24.
11. Delisi LE, Neckers LM, Weinberger DR, Wyatt RJ (1981): Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 38:647-650.
12. Gelders Y, Ceulmans D, Hoppenbrouwers M-L, Reytnjens A, Mesotten F (1985): Ritanserin, a selective serotonin antagonist in chronic schizophrenia. In Proceedings of the Fourth World Congress of Biological Psychiatry. Philadelphia, PA: p 338.
13. Hagan RM, Kilpatrick GJ, Tyers MB (1993): Interactions between 5-HT3 receptors and cerebral dopamine function: Implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology 112:S68-S75.
14. Hamik A, Peroutka S (1989): MCPP interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25:569-575.
15. Hollander E, DeCaria CM, Nitescu A, et al (1992): Serotonergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49:21-28.
16. Hoyer D (1988): Functional correlates of serotonin 5HT1 recognition sites. J Recept Res 8:59-81.
17. Hoyer D, Pazos A, Probst A, Palacios J (1986): Serotonin receptors in the human brain. Brain Res 376:85-96.
18. Iqbal N, Asnis GM, Wetzler S, Kahn RS, Kay SR, van Praag HM (1991): The mcpp challenge test in schizophrenia: Hormonal and behavioral responses. Biol Psychiatry 30:770-778.
19. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993): Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336.
20. Kahn RS, Wetzler S (1991): m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30:1139-1166.
21. Kahn RS, Wetzler S, Asnis GM, van Praag HM (1990): The effects of m-chlorophenylpiperazine in normal subjects: A dose-response study. Psychopharmacology 100:339-344.
22. Kahn RS, Siever LJ, Gabriel S, et al (1992a): Serotonin function in schizophrenia: Effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res 43:1-12.
23. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C (1993a): Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: Implications for the mechanism of action of clozapine. Psychopharmacology 112:S90-S94.
24. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL (1993b): Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry 150:1337-1342.
25. Kahn RS, Davidson M, Siever LJ, Sevy S, Davis KL (1994): Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry 35:909-912.
26. Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group (1988): Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
27. Kay S, Fishbein A, Opler L (1987): The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 14:297-315.
28. Kilkpatrick GJ, Jones BJ, Tyers MB (1987): Identification and distribution of 5-HT3 receptor in rat brain using radioligand binding. Nature 330:746-748.
29. Krystal JH, Seibyl JP, Price LH, et al (1993): m-Chlorophe-nylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 50:624-635.
30. Losconczy MF, Song IS, Mohs RC, et al (1986): Correlates of lateral ventricular size in chronic schizophrenics. I. Behavioral and treatment response measures. Am J Psychiatry 143:976-981.
31. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27.
32. Meltzer HY, Maes M, Lee MA (1993): The cimetidine-induced increase in prolactin secretion in schizophrenia: Effect of clozapine. Psychopharmacology 112:S95-S104.
33. Ninan PT, van Kammen DP, Scheinin M, Linnoila M, Bunney WE Jr, Goodwin FK (1984): CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. Am J Psychiatry 141:566-569.
34. Nyback H, Berggren BM, Hindmarsh T, Sedvall G, Wiesel FA (1983): Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res 9:301-308.
35. Owen RR, Gutierrez-Esteinou R, Hsiao J, et al (1993): Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 50:636-644.
36. Pigott TA, Zohar J, Hill JL, et al (1991): Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive compulsive disorder. Biol Psychiatry 29:418-426.
37. Potkin SG, Weinberger DR, Linnoila M, Wyatt RJ (1983): Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. Am J Psychiatry 140:21-25.
38. Schmidt CJ, Kehne JH, Carr AA, et al (1993): Contribution of serotonin neurotoxins to understanding psychiatric disorders: The role of 5-HT2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol 8(suppl):25-32.
39. Suckow RF, Cooper TB, Kahn RS (1990): High-performance liquid Chromatographic method for analysis for plasma m-chlorophenylpiperazine. J Chromatogr 528:228-234.
40. Szymanski S, Lieberman J, Pollack S, et al (1993): The dopamine-serotonin relationship in clozapine response. Psychopharmacology 112:S85-S89.
41. van Praag HM (1983): CSF 5-HIAA and suicide in nondepressed schizophrenics. Lancet ii:977-978.
42. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL (1987): Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 45:167-172.